References:  1. Beck M et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med.2014;16(10):759–765.   2. Clarke LA et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009;132(1):229–240.   3. Yasuda E et al. Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements. Mol Genet Metab Rep 2015;2:65–76.   4. Shapiro EG et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab 2015;116(1-2):61–68.   5. Muenzer J et al. International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123(1):19–29.   6. Arn P et al. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr 2009;154(6):859–864.e3.   7. Thomas JA et al. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 2010;33(4):421–427.   8. Semenza GL et al. Respiratory complications of mucopolysaccharide storage disorders. Medicine 1988;67(4):209–219.  9. Clarke LA et al. Mucopolysaccharidosis type I. In: Pagon RA et al eds. GeneReviews® Seattle, WA: University of Washington, Seattle; 2002. http://www.ncbi.nlm.nih.gov/books/NBK1162/?report=reader. Accessed July 31, 2015.  10. de Ru MH et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6(55):1–9.